William Baly, MD
Internal Medicine · Orangeburg, SCNPI 1831108919
Payments from drug & device makers
Across 124 payments — averaging $15.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$363
- Lilly USA, LLC$245
- AstraZeneca$207
- AbbVie$200
- Abbott$114
- Boehringer Ingelheim$108
- plus $741 from 20 others
What the payments were for
- Food & beverage$1,977100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 22 | $363 |
| Lilly USA, LLC | 15 | $245 |
| AstraZeneca(2 entities) | 14 | $207 |
| AbbVie | 16 | $200 |
| Abbott | 6 | $114 |
| Boehringer Ingelheim | 6 | $108 |
| Amarin Pharma, Inc. | 7 | $101 |
| Sanofi-aventis U.S. LLC | 4 | $70 |
| Astellas Pharma US Inc | 4 | $65 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $60 |
| Nestle Healthcare Nutrition Inc. | 3 | $59 |
| Novartis | 3 | $52 |
| Esperion Therapeutics, Inc. | 3 | $47 |
| Amgen | 2 | $38 |
| Conmed Corporation | 1 | $33 |
| GSK | 2 | $28 |
| Pfizer | 2 | $24 |
| Merck | 2 | $23 |
| Ultragenyx Pharmaceutical Inc. | 1 | $22 |
| Johnson & Johnson | 1 | $21 |
| Genentech USA, Inc. | 1 | $20 |
| Dexcom, Inc. | 1 | $20 |
| Ironwood Pharmaceuticals, Inc | 1 | $20 |
| Exact Sciences | 1 | $14 |
| Mylan Specialty L.p. | 1 | $14 |
| Sanofi Pasteur Inc. | 1 | $11 |
How this compares
$1,977 in reported general payments places this provider in the 75th percentile of 1,498 internal medicine providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 130 | $136,822 |
| MounjaroTirzepatide | 99 | $113,534 |
| EliquisApixaban | 94 | $88,846 |
| TrulicityDulaglutide | 53 | $67,133 |
| FarxigaDapagliflozin Propanediol | 89 | $62,108 |
| JanuviaSitagliptin Phosphate | 66 | $45,892 |
| XareltoRivaroxaban | 54 | $42,128 |
| JardianceEmpagliflozin | 48 | $38,599 |
| LinzessLinaclotide | 44 | $25,601 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 34 | $25,208 |
| EntrestoSacubitril/Valsartan | 17 | $14,160 |
| JanumetSitagliptin Phos/Metformin Hcl | 17 | $14,158 |
| Bydureon BciseExenatide Microspheres | 16 | $14,060 |
| MyrbetriqMirabegron | 20 | $13,987 |
| TradjentaLinagliptin | 16 | $13,547 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $245 | $180,667152 claims |
| Novo NordiskOzempic | $363 | $136,822130 claims |
| PfizerEliquis | $24 | $88,84694 claims |
| MerckJanuvia, Janumet Xr, Janumet | $23 | $85,258117 claims |
| Boehringer IngelheimJardiance, Tradjenta, Synjardy | $108 | $63,55778 claims |
| AstraZenecaFarxiga | $207 | $62,10889 claims |
| Johnson & JohnsonXarelto | $21 | $42,12854 claims |
| AbbVieLinzess | $200 | $25,60144 claims |
| GSKAnoro Ellipta, Breo Ellipta, Shingrix | $28 | $15,87941 claims |
| NovartisEntresto | $52 | $14,16017 claims |
| Astellas Pharma US IncMyrbetriq | $65 | $13,98720 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,498 internal medicine providers in South Carolina.
Other internal medicine in Orangeburg
- Rubin PatelOrangeburg$183K
- Rica SantiagoMt Pleasant$10.7M
- Richard MillsMt Pleasant$5.5M
- Yvonne DavisMount Pleasant$2.4M
- David BolsterSummerville$2.3M
- Colby GrossmanSummerville$1.4M
- Amit ShahIndian Land$1.4M
- Philip NicolMurrells Inlet$782K
- Carl SofleyAnderson$673K
- Carl MitchellColumbia$564K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.